exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087880 RNA Name: hsa-miR-19a-3p RNA Type: miRNA Chromosome: chr13 Starnd: + Coordinate: Start Site(bp): 91350939 End Site(bp): 91350961 External Links: hsa-miR-19a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ATP6V1B2 chr8 20197381 20226819 + BCL7A chr12 122019422 122062044 + BRWD1 chr21 39184176 39321559 - BTBD7 chr14 93237550 93333092 - CAMTA1 chr1 6785454 7769706 + CASP2 chr7 143288215 143307696 + CCDC47 chr17 63745255 63776351 - DNAJC16 chr1 15526813 15592379 + HIP1 chr7 75533298 75738962 - HOMER1 chr5 79372636 79514134 - MEF2D chr1 156463727 156500779 - MYLIP chr6 16129086 16148248 + RCOR1 chr14 102592649 102730561 + RFX1 chr19 13961530 14007039 - RPS23 chr5 82273320 82278396 - TMEM181 chr6 158536436 158635428 + ATF7IP chr12 14365632 14502935 + CAMSAP1 chr9 135808487 135907546 - CDS1 chr4 84583127 84651334 + CHIC1 chrX 73563200 73687102 + DTL chr1 212035553 212107400 + MARCKS chr6 113857345 113863475 + SCYL2 chr12 100267140 100341715 + SPAG7 chr17 4959226 4967817 - SPOPL chr2 138501770 138573547 + STK33 chr11 8391868 8594289 - TNFRSF12A chr16 3018445 3022383 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0001186 chr21 35475133 35475818 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC010997.3 chr10 75279726 75401246 - AC011498.2 chr19 4447304 4448217 + AC011503.2 chr19 23927788 23929287 + AC021078.1 chr5 149494314 149504670 - AC135050.6 chr16 31122235 31124064 + AL049840.4 chr14 103694516 103695050 - AL158206.1 chr9 19453209 19455173 + AL158825.2 chr9 75009828 75016036 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - LAMTOR5-AS1 chr1 110347116 110443817 + LINC00667 chr18 5237826 5290608 + MCM3AP-AS1 chr21 46229196 46259390 + NEAT1 chr11 65422774 65445540 + SNHG20 chr17 77086716 77099902 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.